#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mantle cell lymphoma recurrent Cognitive disorder Arrhythmogenic right ventricular dysplasia Oesophageal achalasia Fabry's disease Arginase deficiency Acquired C1 inhibitor deficiency Hyperinsulinaemic hypoglycaemia Oesophageal adenocarcinoma Neuroendocrine tumour of the lung Hereditary ataxia Liposarcoma metastatic Hepatoblastoma Niemann-Pick disease Haemolytic uraemic syndrome More trials…

    Learn about Rare Diseases

    Uterine leiomyosarcoma – Life with Disease Glomerulonephritis membranoproliferative – Life with Disease Biotinidase deficiency – Trials in Disease Medulloblastoma recurrent Undifferentiated sarcoma – Treatment Turner’s syndrome – Diagnostics Chronic granulomatous disease Haemophilia – Treatment Hepatoblastoma – Treatment Alport’s syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    APAZUNERSEN RIVASTIGMINE Tisotumab Vedotin Donidalorsen Ab-1002 Betula Pendula Pollen Extract SECRETIN SYNTHETIC HUMAN Sulfamethizole Ertapenem Sodium Avatrombopag Rbl012.2 LIPASE Lonvoguran TETRODOTOXIN Rasagiline Medi0618 Siponimod Treg02 Tiragolumab Ephedrine Hydrochloride More therapies…

    Learn about Your Condition

    Biliary tract operation Factor IX deficiency Phaeochromocytoma Cardiac failure congestive Nephroblastoma Medication overuse headache Amnestic disorder Cerebral palsy Abdominal wall pain Pustular psoriasis Pulmonary hypertension Cholangiocarcinoma Vulvovaginal dryness Myxoid liposarcoma Pouchitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Cholangiocarcinoma

  • A Study Testing BNT329 Safety and Effectiveness in Patients With Advanced Solid Tumors That Express the CA19-9 Tumor Marker

    Recruiting

    2 1 1
    Investigated Diseases:
    • Colorectal adenocarcinoma
    • Endometrial cancer
    • Oesophageal adenocarcinoma
    Germany Spain

  • Study of gemcitabine, cisplatin, and pembrolizumab before and after surgery compared to surgery alone for patients with bile duct cancer

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Cholangiocarcinoma
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine
    • Pembrolizumab
    The Netherlands

  • Testing trifluridine, tipiracil and nanoliposomal irinotecan combination for patients with bile duct or gallbladder cancer after previous treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Gallbladder cancer
    • Cholangiocarcinoma
    Investigated Drugs:
    • Tipiracil Hydrochloride
    • Trifluridine
    • Irinotecan
    Germany

  • Study of ivosidenib maintenance treatment in patients with IDH1-mutated cholangiocarcinoma after standard chemotherapy

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Cholangiocarcinoma
    Investigated Drugs:
    • Ivosidenib
    Germany

  • Evaluating 68Ga-FAPI-46 PET/CT Scanning for Improved Diagnosis in Patients with Pancreatic Cancer or Bile Duct Cancer Eligible for Curative Treatment

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    • Gallium (68Ga) Chloride
    • Germanium (68Ge) Chloride
    France

  • Study on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Pleural mesothelioma
    • Primary amyloidosis
    • Malignant melanoma
    Investigated Drugs:
    • Atezolizumab
    • Cemiplimab
    • Daratumumab
    France
1 2 3 … 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!